Abstract
Clinical course after first episode psychosis (FEP) is heterogeneous. Subgrouping longitudinal symptom trajectories after FEP would be useful for developing personalized treatment approaches, and being able to predict these trajectories at baseline would facilitate individual-level treatment planning. We utilized k-means clustering to identify distinct clusters of 411 FEP patients based on longitudinal positive and negative symptom patterns. Ridge logistic regression was then used to identify predictors of cluster membership using baseline data. Three clusters were identified, demonstrating unique demographic, clinical and treatment response profiles. Cluster 1 exhibits lower positive and negative symptoms (LS), lower antipsychotic dose, and relatively higher affective psychosis; Cluster 2 shows lower positive symptoms, persistent negative symptoms (LPPN), and intermediate antipsychotic doses; Cluster 3 presents persistently high levels of both positive and negative symptoms (PPNS), as well as higher antipsychotic doses. We effectively predicted patients’ cluster membership (AUC of 0.74). The most important predictive features included contrasting trends of apathy, affective flattening, and anhedonia for the LS and LPPN clusters. Global hallucination severity, positive thought disorder and manic hostility predicted PPNS. These results help parse the heterogeneity of FEP trajectories and may facilitate the development of personalized treatment approaches tailored to cluster characteristics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Douglas Research Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
